CatSci Ltd chooses Anaplan & Bedford Consulting to achieve ambitious growth plans
Share
Related Posts
CatSci Ltd, an award-winning innovation partner supporting global pharmaceutical companies to deliver life-changing therapeutics to patients around the world has selected Anaplan as a platform to support its exciting growth journey.
CatSci has recently received significant investment from Keensight Capital. This will support the continued growth of its core business via capability and site expansion, as well as the development of GMP capabilities and the expansion of its offering in oligonucleotide services. The Anaplan platform will enable a Zero-Based-Budgeting approach next fiscal year that will help the organisation proactively manage costs, whilst simultaneously delivering exponential growth.
“It became clear that our previous business planning processes in spreadsheets and legacy tools would not be sustainable to support our growth plans. Having experience of Anaplan at a previous company, we knew that it was the right platform to enable CatSci on its growth trajectory, whilst giving time back to the team to spend on value-add activities.” Mark Bate, CFO, CatSci
“Given the critical importance of the work CatSci does within the pharmaceutical industry, supporting early and late phase drug development, we’re thrilled to welcome CatSci into the Anaplan Community. CatSci are on an exciting growth path to quadruple in size over the next few years and the Anaplan platform will sit at the heart of CatSci’s Digital Transformation to underpin this growth.” Pete Dixon, Commercial Manager, Anaplan
To learn more about the ways Anaplan helps businesses deliver on their strategic objectives through effective planning, visit Anaplan here
To learn more about CatSci’s innovative and award-winning drug development capabilities, click here
About CatSci
CatSci Ltd is an award-winning innovation partner, dedicated to breaking down the silos in drug development to accelerate the delivery of life-changing medicines to patients in need. We proudly serve customers across the globe with projects, meeting their needs from candidate selection to product launch and beyond. Our tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, we provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. We possess a range of critical enabling technologies including catalysis, material science, pre-formulation, analytical development and HPAPI development.
Agile, commercially minded and scientifically led, CatSci leverages its highly qualified technical team and state-of-the-art facilities to empower our customers to create affordable, best-in-class small molecule therapeutics in a safer, greener and more cost-effective way. Together, we can meet the evolving healthcare needs of the world.
CatSci works efficiently with your preferred partners, while continually strengthening our own industry-leading partnerships across the pharmaceutical supply chain, to address your dynamic drug substance development needs. A true extension of your team, we are a dependable, trusted partner for innovation that takes the time to understand your project objectives and provide you with perfect-for-purpose chemistry services.
Recent recognition includes the highly esteemed Queen’s Award for Enterprise: International Trade 2022, the 2022 Bionow Awards (Export of the Year), the 2022 Inspire Business Awards (Business of the Year (25+ employees)), the 2022 Wales Business Awards (Workplace Wellbeing), the 2022 Wales STEM Awards (STEM Company of the Year (50+ Employees) and STEM Ambassador of the Year), and the 2022 Cardiff Business Award (International Business of the Year).
© CatSci Ltd, 2022.
Editorial enquiries:
Caitlin Bourton
caitlin.bourton@catsci.com
